Healthcare Industry News: HSMN NewsFeed

Devices Orthopaedic

 News Release - October 22, 2010

Wright Medical Group, Inc. Announces Full Commercial Launch of PRO-STIM(TM) Osteoinductive Bone Graft Substitute

Clinically-Tested Osteoinductive Composite Expands Market for Wright’s Proprietary PRO-DENSE® Grafting Platform

ARLINGTON, Tenn.--(Healthcare Sales & Marketing Network)-- Wright Medical Group, Inc. (NASDAQ:WMGI ), a global orthopaedic medical device company, is pleased to announce the full commercial launch of PRO-STIM™ Injectable Inductive Graft. PRO-STIM™ graft is a novel composite grafting material that is injected through a small needle or digitally implanted, hardens, and is replaced by the patient’s new bone over time. Building on the clinical success of Wright’s PRO-DENSE® material platform, PRO-STIM™ graft provides surgeons with the osteoconductive base material (a patented combination of calcium sulfate and calcium phosphate materials), but adds a high volume of osteoinductive demineralized bone matrix (DBM) to the formulation to speed the healing and remodeling process. In Wright’s pivotal pre-clinical testing, PRO-STIM™ graft outperformed autograft bone - long considered the grafting “gold standard” - at 8 weeks.

“Our pre-clinical model showed accelerated healing compared to autograft, suggesting a superiority to autograft that could be very beneficial for human use in the restoration of skeletal or bone defects,” said Thomas Turner, D.V.M., Assistant Professor at Rush University Medical Center in Chicago and principle investigator for the pre-clinical model. “In fact, the new bone repair noted in the PRO-STIM™-treated defects was equivalent, if not better than, normal unoperated bone, indicating fast, efficient remodeling to a more normal state.”

Receiving FDA clearance in September 2009, PRO-STIM™ graft was released in a controlled fashion to select institutions to confirm human effectiveness over a 13-month period. “This has been a very controlled product release,” stated Rick Swaim, Director of Wright's Biologics Marketing team. “Extra time and resources were invested in order to generate strong clinical experience prior to our full-scale commercial release. Based on clinical experience in over 600 procedures performed at top orthopaedic centers, we are confident that PRO-STIM™ graft will deliver results very consistent with our pre-clinical [animal trial] results.”

Michael D. Neel, M.D. of mid-south orthopaedic practice OrthoMemphis commented, “PRO-STIM™ graft gives the surgeon a viable alternative to autograft without the complications associated with the donor site. This new, novel option provides a proven, flowable, composite bone graft that adds demineralized bone matrix (DBM) to enhance healing and remodeling into native bone. This hardening material has been useful in my orthopaedic practice for both open and percutaneous applications such as bone cysts and core decompressions of the hip.”

“I’ve used PRO-STIM™ graft in several foot and ankle reconstruction cases to date and have had excellent results,” noted Robert D. Santrock, M.D. of Midlands Orthopaedics in Columbia, South Carolina. “The injectability and ease of use allows for simple efficient application and has resulted in good bony fusions in some very challenging patients.”

PRO-STIM™ Injectable Inductive Graft will be made available immediately in the U.S. and select international countries through Wright's direct and distributor-based sales force. PRO-STIM™ graft is the latest addition to Wright’s Biologics franchise, which includes products such as XPANSION® Micrografting System, PRO-DENSE® Injectable Regenerative Graft, GRAFTJACKET® Regenerative Tissue Matrix, BIOTAPE XM® Reinforcement Matrix, OSTEOSET® T Medicated Bone Graft (not available in the U.S.), and the ALLOPURE® line of foot and ankle bone wedges.

Wright Medical Group, Inc. is a global orthopaedic medical device company and a leading provider of surgical solutions for the foot and ankle market. The Company specializes in the design, manufacture and marketing of devices and biologic products for extremity, hip and knee repair and reconstruction. The Company has been in business for 60 years and markets its products in over 60 countries worldwide. For more information about Wright Medical, visit the Company’s website at

This press release contains “forward-looking statements” as defined under U.S. federal securities laws. These statements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations and express management’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Such risks and uncertainties include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009, under the heading, “Risk Factors”). Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date of this press release, and we undertake no obligation to update such statements after this date.

Source: Wright Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

Send This Story to a Friend

RepFinder USA - Find Great Medical Independent Sales Reps without recruiter or finder's fees.RepFinder USA - available on the Apple App Store for iPhone and iPad.